Phase II
Pharma and biotech companies from Asia to Europe provide updates on business and clinical activities.
TLC announced the earlier-than-scheduled full enrollment in Part 1 of TLC590’s Phase II clinical trial in patients following bunionectomy.
The latest job cuts at Merrimack come about five months after the company culled 60 percent of its staff.
Across the globe, pharma and biotech companies report deals and pipeline updates, with news from Boehringer Ingelheim, Metrion, Elvie, and more.
Public perception of the industry can be a bit confusing. Life Science Leader recently pulled together several biopharma executives for a round table discussion of the biopharma industry’s public perception—generally bad—and what might be able to do about it.
The California-based company also shared positive early data from a beta thalassemia study and announced plans to increase AAV manufacturing.
Good safety profile and encouraging efficacy reported for recurrent glioblastoma patients with disrupted blood-brain barrier
The American Association for Cancer Research (AACR) Annual Meeting is taking place in Atlanta. Here’s a look at just a few stories coming out of the meeting.
NOXXON Pharma N.V. announced the latest update of clinical results from the Phase 1/2 study of NOX-A12 in combination with Keytruda® in patients with microsatellite-stable, metastatic pancreatic and colorectal cancer in a poster presentation at the American Association for Cancer Research Annual Meeting.
MD Anderson Phase II trial shows drug well tolerated with high response rates for marginal zone lymphoma
PRESS RELEASES